Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies for the management of pain and other central nervous system (CNS) disorders. The Company’s product, AXS-02 is an oral, targeted and non-opioid therapeutic for chronic pain. It is developing AXS-02 for the treatment of pain in three conditions: complex regional pain syndrome (CRPS); knee osteoarthritis associated with bone marrow lesions (BMLs); and chronic low back pain (CLBP), associated with type 1 or mixed type 1 and type 2 Modic changes (MCs). Its AXS-05 is a fixed-dose combination of dextromethorphan (DM) and bupropion. It is developing AXS-05 for the treatment of two conditions: treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD). Its AXS-05 has completed Phase II trials. The Company also have one active program, AXS-06, in preclinical development, which is developed for the treatment of chronic pain disorders.
